Zacks Investment Research on MSN

MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Moderna cancer therapy with Merck’s Keytruda cut mortality by 49% in mid-stage trial

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
BioSpace

Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...